Inhibace

Cilazapril, the active ingredient in Inhibace, is an ACE inhibitor presented as an oral dosage form for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Inhibace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cilazapril belongs to the ACE inhibitor class and is employed in conditions where the renin‑angiotensin system contributes to elevated blood pressure or cardiac overload. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: improves ventricular function and decreases mortality in chronic heart failure. - Post‑myocardial infarction: helps prevent remodeling and reduces the chance of subsequent cardiac events.

Cilazapril may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Persistent dry cough - Dizziness or light‑headedness - Headache - Fatigue - Taste disturbance - Mild rash

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Hyperkalemia (elevated potassium levels) - Acute renal failure - Hepatotoxicity - Anaphylactic reactions

Before initiating Cilazapril therapy, several safety considerations should be observed. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR, especially in patients with existing kidney disease. - Electrolyte surveillance: monitor potassium levels to detect hyperkalemia. - History of angioedema: avoid use in patients with prior ACE‑inhibitor‑related swelling. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Cilazapril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment and hyperkalemia. - Lithium: concurrent use can raise lithium concentrations, leading to toxicity. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Loop or thiazide diuretics: may increase risk of hypotension, especially at therapy start. - Beta‑blockers: additive blood‑pressure lowering effect; monitor for bradycardia.